Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

← catalyst calendar

NCT05445778 · readout ≤ 254 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With GOG Foundation.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

520actual

Sites

264

Countries

Argentina, Australia, Belgium +19

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-03-15

actual

When the study began enrolling

Primary completion

Apr 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

May 2032

estimated

The whole study's end, after follow-up

First posted

2022-07-06

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-02

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions

Drug: Mirvetuximab soravtansine plus Bevacizumab — also filed as MIRV
Drug: Bevacizumab

Primary outcome

what the primary-completion date above is the date OF

Assess Progression-free survival (PFS)

measured Up to 4 years

Publications

PMID 39082675 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed